MediciNova, Inc.
MNOVHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeMediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company carries a $68.4M market cap, placing it firmly in the micro-cap category. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Market Cap
$68.4M
Beta
0.61
P/E (TTM)
—
P/E (Fwd)
-2.70
EPS (TTM)
$-0.21
EPS (Fwd)
$-0.52
ROE
-25.6%
ROA
-16.4%
Cash
$25.4M
Total Debt
$117,038
Free CF
-$5.7M
52W Change
13.0%
Annual Financials
Cash vs Debt
Where MNOV stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MNOV finished 7.28% below its 150-day moving average ($1.51) and 7.28% below its 200-day moving average ($1.51). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MNOV overbought or oversold?
At the October 20, 2026 close, MNOV's RSI(14) was 19.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
MediciNova, Inc. holds $25.4M in cash against $117K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$5.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -25.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $4.0M to $410K.
With a beta below 0.7, MediciNova, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, MNOV has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing MNOV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.